Altered molecular repertoire of immune system by renal dysfunction in the elderly: is prediction and targeted prevention in the horizon?

EPMA Journal

Kuo-Cheng Lu²  Chih-Kang Chiang³  Kuan-Yu Hung³  Min-Hui Wang²  Cheng-Lin Lang¹ 

[1] Division of Nephrology, Department of Internal Medicine, Cardinal Tien Hospital, Yong-He Branch, Taipei 234, Taiwan;Division of Nephrology, Department of Internal Medicine, Cardinal Tien Hospital & School of Medicine, Fu-Jen Catholic University, New Taipei City 231, Taiwan;Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital & College of Medicine, National Taiwan University, Taipei 10048, Taiwan

关键词: Target prevention;    Integrative medical approach;    Immunosenescence;    Vitamin D;    Hemodialysis;    Age;    T cell differentiation;   

Others  :  801544
DOI  :  10.1186/1878-5085-4-17

 received in 2013-04-07, accepted in 2013-06-13,  发布年份 2013

【 摘 要 】

Background

Patients on chronic hemodialysis (HD) have impaired cellular and humoral immunity. The percentage of elderly people among the total population in Taiwan is increasing dramatically, and HD is the primary alternative for renal replacement therapy when renal function declines. Activated vitamin D is widely used in HD patients with secondary hyperparathyroidism (SHPT) and is a well-known immunomodulatory agent. Personalized medicine and integrative medical approach has been a trend in current clinical practice. Can we improve their immune function using vitamin D in spite of the mineral aspect? Here, we investigated the relationship between serum 25-hydroxyvitamin D (25(OH)D) level and T cell differentiation in chronic HD patients.

Methods

Forty patients with chronic HD were enrolled. HD patients with SHPT had been treated with activated vitamin D for 3 months. Peripheral blood mononuclear cells obtained from the patients were cultured and stimulated by mitogens, and T cells were analyzed by flow cytometry. Serum 25(OH)D levels were detected by enzyme-linked immunosorbent assay.

Results

The incidence of T cell differentiation to the T helper cell (Th)2 subtype was more prevalent in the elderly group than in the controls (p = 0.001). Th2 differentiation was also correlated with age (p = 0.004) and serum 25(OH)D levels (p < 0.05). After treated with activated vitamin D, the level of Th1 cytokines decreased while the Th2 cytokine level increased in the sera (p < 0.05). The T cell differentiation tended toward the Th2 subtype (p = 0.027) after treatment of activated vitamin D in SHPT patients.

Conclusions

These results demonstrated that Th2 differentiation is correlated with age and the serum 25(OH)D level of patients. Treatment with activated vitamin D influenced T cell differentiation and cytokine expression in SHPT patients. Taking vitamin D is the possible prediction and targeted treatment in the immune dysfunction in chronic HD patients.

【 授权许可】

   
2013 Lang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello CA, Shaldon S, Koch KM: Gene expression of interleukin-1 beta during hemodialysis. Kidney Int 1993, 43:712-721.
• [2]Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde KH, Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995, 47:559-565.
• [3]Lisowska KA, Debska-Slizien A, Jasiulewicz A, Heleniak Z, Bryl E, Witkowski JM: Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes. J Clin Immunol 2012, 32:189-200.
• [4]Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P: Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995, 154:882-892.
• [5]Fernandez-Fresnedo G, Ramos MA, Gonzalez-Pardo MC, de Francisco AL, Lopez-Hoyos M, Arias M: B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 2000, 15:502-510.
• [6]Fleming SJ, Moran DM, Cooksley WG, Faoagali JL: Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect 1991, 22:251-257.
• [7]Kreft B, Klouche M, Kreft R, Kirchner H, Sack K: Low efficiency of active immunization against diphtheria in chronic hemodialysis patients. Kidney Int 1997, 52:212-216.
• [8]Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS: Increased incidence of malignancy during chronic renal failure. Lancet 1975, 1:883-886.
• [9]Oliva JS, Roa LM, Lara A, Garrido S, Salgueira M, Palma A, Milán JA, Martín-Reyes G: Survival and factors predicting mortality in hemodialysis patients over 75 years old. J Nephrol 2013, 26:129-135.
• [10]Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R: Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001, 98:6800-6805.
• [11]Guillot X, Semerano L, Saidenberg-Kermanac’h N, Falgarone G, Boissier MC: Vitamin D and inflammation. Joint Bone Spine 2010, 77:552-557.
• [12]Wu CC, Chang JH, Chen CC, Su SB, Yang LK, Ma WY, Zheng CM, Diang LK, Lu KC: Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med 2011, 223:153-159.
• [13]Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE: Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179:1634-1647.
• [14]Dorr J, Doring A, Paul F: Can we prevent or treat multiple sclerosis by individualised vitamin D supply? EPMA J 2013, 4:4. BioMed Central Full Text
• [15]Lu KC, Tseng CF, Wu CC, Yeung LK, Chen JS, Chao TY, Janckila AJ, Yam LT, Chu P: Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism. Blood Purif 2006, 24:423-430.
• [16]Castle SC, Uyemura K, Fulop T, Makinodan T: Host resistance and immune responses in advanced age. Clin Geriatr Med 2007, 23:463-479.
• [17]Desai A, Grolleau-Julius A, Yung R: Leukocyte function in the aging immune system. J Leukoc Biol 2010, 87:1001-1009.
• [18]Fulop T, Larbi A, Hirokawa K, Mocchegiani E, Lesourds B, Castle S, Wikby A, Franceschi C, Pawelec G: Immunosupportive therapies in aging. Clin Interv Aging 2007, 2:33-54.
• [19]Bohler T, Canivet C, Nguyen PN, Galvani S, Thomsen M, Durand D, Salvayre R, Negre-Salvayre A, Rostaing L, Kamar N: Cytokines correlate with age in healthy volunteers, dialysis patients and kidney-transplant patients. Cytokine 2009, 45:169-173.
• [20]Ginaldi L, De Martinis M, D’Ostilio A, Marini L, Loreto MF, Corsi MP, Quaglino D: The immune system in the elderly: I. Specific humoral immunity. Immunol Res 1999, 20:101-108.
• [21]Ginaldi L, De Martinis M, D’Ostilio A, Marini L, Loreto MF, Martorelli V, Quaglino D: The immune system in the elderly: II. Specific cellular immunity. Immunol Res 1999, 20:109-115.
• [22]Shearer GM: Th1/Th2 changes in aging. Mech Ageing Dev 1997, 94:1-5.
• [23]Libetta C, Rampino T, Dal CA: Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis 2001, 38:286-295.
• [24]Borges A, Borges M, Fernandes J, Nascimento H, Sameiro-Faria M, Miranda V, Reis F, Belo L, Costa E, Santos-Silva A: Apoptosis of peripheral CD4(+) T-lymphocytes in end-stage renal disease patients under hemodialysis and rhEPO therapies. Ren Fail 2011, 33:138-143.
• [25]Libetta C, Sepe V, Dal CA: Bio-incompatibility and Th2 polarization during regular dialysis treatment. Int Rev Immunol 2010, 29:608-625.
• [26]Alvarez-Lara MA, Carracedo J, Ramirez R, Martin-Malo A, Rodriguez M, Madueno JA, Aljama P: The imbalance in the ratio of Th1 and Th2 helper lymphocytes in uraemia is mediated by an increased apoptosis of Th1 subset. Nephrol Dial Transplant 2004, 19:3084-3090.
• [27]Effros RB: Replicative senescence of CD8 T cells: effect on human ageing. Exp Gerontol 2004, 39:517-524.
• [28]Patel NM, Gutierrez OM, Andress DL, Coyne DW, Levin A, Wolf M: Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 2010, 77:715-720.
• [29]Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49:1063-1069.
• [30]Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
• [31]Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72:1004-1013.
• [32]Golubnitschaja O, Costigliola V: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for predictive, preventive and personalised medicine. EPMA J 2012, 3:14. BioMed Central Full Text
• [33]Gupta S: Molecular mechanisms of apoptosis in the cells of the immune system in human aging. Immunol Rev 2005, 205:114-129.
• [34]Li H, Manwani B, Leng SX: Frailty, inflammation, and immunity. Aging Dis 2011, 2:466-473.
• [35]Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I: Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007, 20:440-451.
• [36]Huang KC, Hsu SP, Yang CC, Ou-Yang P, Lee KT, Morisawa S, Otsubo K, Chien CT: Electrolysed-reduced water dialysate improves T-cell damage in end-stage renal disease patients with chronic haemodialysis. Nephrol Dial Transplant 2010, 25:2730-2737.
• [37]Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW: Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003, 42:524-531.